Entrectinib: An orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors Journal Article

   

Authors:	Liu, D.; Offin, M.; Harnicar, S.; Li, B. T.; Drilon, A.
Article Title:	Entrectinib: An orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
Abstract:	Entrectinib is a potent small-molecule tyrosine kinase inhibitor that targets oncogenic rearrangements in NTRK, ROS1, and ALK. The consolidated results of 2 Phase I trials demonstrated activity in tyrosine kinase inhibitor-naïve patients along with substantial intracranial activity. In ROS1-rearranged lung cancers, entrectinib results in durable disease control and prolonged progression-free survival. The drug is well tolerated and has a safety profile that includes adverse events mediated by on-target tropomyosin-related kinase A/B/C inhibition. © 2018 Liu et al.
Keywords:	lung cancer; alk; nsclc; trk; ros1; entrectinib
Journal Title:	Therapeutics and Clinical Risk Management
Volume:	14
ISSN:	1176-6336
Publisher:	Dove Medical Press Ltd
Date Published:	2018-07-20
Start Page:	1247
End Page:	1252
Language:	English
DOI:	10.2147/tcrm.s147381
PROVIDER:	scopus
PMCID:	PMC6055893
PUBMED:	30050303
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85058463128&doi=10.2147%2fTCRM.S147381&partnerID=40&md5=c5c6c082dd97d3458c0f884f4f1f00f0
Notes:	Ther. Clin. Risk Manage. -- Export Date: 2 January 2019 -- Review -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/136607